secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2023-04-11T23:59:59+00:00
Accession:  0001193125-23-097389
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotech COO Mark Adams terminated; duties absorbed by President Rubinstein
--------------------------------------------------------------------------------

- Mark Adams, COO, was informed on April 7, 2023, that his service will be terminated by May 2023.
- President Julie Rubinstein will assume the Chief Operating Officer's duties.
- No replacement COO has been named; organizational impact remains unclear.
- Chad Robins continues as CEO; leadership transition underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000119312523097389/0001193125-23-097389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000119312523097389/d497018d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-097389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer